+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dry Eye Disease - Epidemiology Forecast - 2034

  • PDF Icon

    Report

  • 151 Pages
  • December 2024
  • Region: Global
  • DelveInsight
  • ID: 5524490
Description Jump to:

Key Highlights

  • In 2023, the total diagnosed prevalence of Dry eye disease (DED) was highest in the US among the 7MM, accounting for nearly 22.47 million cases which is further expected to increase by 2034.
  • In Japan, in 2023, ~2,341 thousand males and ~ 8.29 million females were affected with Dry eye disease (DED). estimates that these numbers might increase by 2034.
  • In 2023, the UK reported ~2,811 thousand mild, ~1,345 thousand moderate, and ~1,956 thousand severe cases of DED. Analysis by experts indicates that the overall severity-specific cases of DED are expected to rise in the coming years.
  • The Dry Eye Disease (DED) cases are expanding due to increasing prevalence, rising awareness and better diagnostic capabilities, which increase demand for treatments. Advancements in research, increased funding for rare diseases, and the development of novel therapies are also key drivers.
  • As per estimates, Japan accounted for nearly 19% of the Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the 7MM in 2023.
The “Dry Eye Disease (DED) - Epidemiology Forecast - 2034” report delivers an in-depth understanding of Dry Eye Disease (DED), historical and forecasted epidemiology of Dry Eye Disease (DED) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

Study Period: 2020-2034

Dry Eye Disease (DED) Disease Understanding

Dry Eye Disease (DED) Overview

DED, which is also known as dry eye disease or keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface due to a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities.

The most common cause of DED is hormonal changes which lead to poor functioning of the tear glands and reduced secretion of tears.

Dry Eye Disease (DED) Diagnosis

Diagnosing DED involves a comprehensive eye examination, including an assessment of symptoms, tear production, and eye surface health. Various diagnostic tests may be used, such as the Schirmer's test to measure tear production, tear breakup time to assess tear film stability, and ocular surface staining with dyes to detect damage. Additionally, a thorough medical history and evaluation of contributing factors like medications or environmental conditions are essential for an accurate diagnosis.

Despite advancements in DED diagnosis, significant unmet needs still persist. Many patients experience delays due to lack of standardized diagnostic criteria and reliance on subjective symptoms. Enhanced diagnostic tools and more precise, objective measures are crucial to improve early detection, accurately gauge disease severity, and tailor effective treatment strategies, ultimately reducing patient discomfort and healthcare burden.

Dry Eye Disease (DED) Epidemiology

For the purpose of designing the patient-based model for the Dry Eye Disease (DED) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of DED, Gender-specific Diagnosed Prevalent Cases of DED, Age-specific Diagnosed Prevalent Cases of DED, and Severity-specific Diagnosed Prevalent Cases of DED in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
  • In the assessment done, the estimated total diagnosed prevalent cases of DED in the 7MM were nearly 54.69 million in 2023.
  • Among the European countries, the United Kingdom had the highest diagnosed prevalent cases of DED with ~6,112 thousand cases, followed by Germany, which had diagnosed prevalent population of ~5,004 thousand in 2023. On the other hand, Spain had the lowest prevalent population (2,064 thousand cases).
  • The US reported the highest number of total diagnosed prevalent cases of DED among the 7MM countries with 41% whereas Japan reported the least cases (19%). This trend is anticipated to be followed during the forecast period as well.
  • In the US, gender-specific diagnosed prevalent cases of DED revealed ~9,439 thousand cases among males and approximately ~13,035 thousand cases among females. Projections indicate that by 2034, the prevalence among females will surpass that of males.
  • The analysis shows that the UK reported the highest number of DED cases in individuals aged 50 and older, with ~4,889 thousand cases. This was followed by ~691 thousand cases in the 40-49 age group and ~532 thousand cases in the 18-39 age group. Projections indicate that the UK is expected to continue leading in these figures by 2034.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Harvard Medical School, Boston, Massachusetts, US University of Pikeville, Kentucky College of Optometry, Pikeville, Kentucky, US; Magdeburg-Stendal University of Applied Sciences, Stendal, Sachsen-Anhalt, Germany; Department of Ophthalmology, Dijon University Hospital, Dijon, France; University of Milan, Milan, Italy; Optometry and Vision Science, Aston University, Birmingham, UK and Ryogoku Eye Clinic, Tokyo, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

  • The report covers a segment of key events, an executive summary, descriptive overview of Dry Eye Disease (DED), explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
  • The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
  • A detailed review of current challenges in establishing the diagnosis.

Dry Eye Disease (DED) Report Insights

  • Patient Population
  • Country-wise Epidemiology Distribution
  • Total Diagnosed Prevalent Cases of DED
  • Gender-specific Diagnosed Prevalent Cases of DED
  • Age-specific Diagnosed Prevalent Cases of DED
  • Severity-specific Diagnosed Prevalent Cases of DED

Dry Eye Disease (DED) Report Key Strengths

  • 11 years Forecast
  • The 7MM Coverage
  • Dry Eye Disease (DED) Epidemiology Segmentation

Dry Eye Disease (DED) Report Assessment

  • Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

  • What are the disease risk, burdens, and unmet needs of Dry Eye Disease (DED)? What will be the growth opportunities across the 7MM concerning the patient population of Dry Eye Disease (DED)?
  • What is the historical and forecasted Dry Eye Disease (DED) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
  • Why is the diagnosed prevalent cases of Dry Eye Disease (DED) in Japan lower than the US?
  • Which country has a high patient share for Dry Eye Disease (DED)?

Reasons to Buy

  • Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the Dry Eye Disease (DED) prevalence cases in varying geographies over the coming years.
  • A detailed overview of Gender and Age Grade-specific diagnosed prevalence of Dry Eye Disease (DED), along with diagnosed prevalence of Dry Eye Disease (DED) Based on severity of airflow limitation and diagnosed prevalence of Dry Eye Disease (DED) based on symptoms and exacerbation history.
  • To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Dry Eye Disease (DED) Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Dry Eye Disease (DED) cases in 2023?

The highest cases of Dry Eye Disease (DED) was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Dry Eye Disease (DED) cases in 2023?

The highest cases of Dry Eye Disease (DED) were found in the US among the 7MM in 2023.

Table of Contents

1. Key Insights2. Report Introduction
3. Dry Eye Disease (DED) Epidemiology Overview at a Glance
3.1. Patient Share Distribution of DED in 2020
3.2. Patient Share Distribution of DED in 2034
4. Epidemiology Methodology of DED5. Executive Summary of Dry Eye Disease (DED)6. Key Events
7. Disease Background and Overview
7.1. Introduction
7.2. Tear Film Working
7.3. Etiology
7.4. Risk Factors
7.5. Pathophysiology
7.6. Symptoms and Clinical Presentations
7.7. Diagnosis
7.7.1. Diagnostic Criteria
7.7.1.1. Comparison of Dry Eye Definition and Diagnostic Criteria between JDES/ADES and DEWS II
7.7.1.2. Diagnostic Criteria of the JDES, 1995 Version
7.7.1.3. Diagnostic criteria of DED proposed by the JDES (2006 version)
7.7.2. Differential Diagnosis
7.7.3. Diagnostic Algorithm
7.7.4. Diagnostic Scheme
7.7.5. Diagnostic Guidelines
7.7.5.1. Dry Eye Syndrome Preferred Practice Pattern guidelines by American Academy of Ophthalmology
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale: The 7MM
8.2.1. Diagnosed Prevalence of DED
8.2.2. Gender-specific Prevalence of DED
8.2.3. Age-specific Diagnosed Prevalence of DED
8.2.4. Severity-specific Diagnosed Prevalence of DED
8.3. Total Diagnosed Prevalent Cases of DED in the 7MM
8.4. The United States
8.4.1. Total Diagnosed Prevalent Cases of DED
8.4.2. Gender-specific Diagnosed Prevalent Cases of DED
8.4.3. Age-specific Diagnosed Prevalent Cases of DED
8.4.4. Severity-specific Diagnosed Prevalent Cases of DED
8.5. EU4 and the UK
8.5.1. Germany
8.5.1.1. Total Diagnosed Prevalent Cases of DED in Germany in Germany
8.5.1.2. Gender-specific Diagnosed Prevalent Cases of DED in Germany
8.5.1.3. Age-specific Diagnosed Prevalent Cases of DED in Germany
8.5.1.4. Severity-specific Diagnosed Prevalent Cases of DED in Germany
8.5.2. France
8.5.2.1. Total Diagnosed Prevalent Cases of DED in France
8.5.2.2. Gender-specific Diagnosed Prevalent Cases of DED in France
8.5.2.3. Age-specific Diagnosed Prevalent Cases of DED in France
8.5.2.4. Severity-specific Diagnosed Prevalent Cases of DED in France
8.5.3. Italy
8.5.3.1. Total Diagnosed Prevalent Cases of DED in Italy
8.5.3.2. Gender-specific Diagnosed Prevalent Cases of DED in Italy
8.5.3.3. Age-specific Diagnosed Prevalent Cases of DED in Italy
8.5.3.4. Severity-specific Diagnosed Prevalent Cases of DED in Italy
8.5.4. Spain
8.5.4.1. Total Diagnosed Prevalent Cases of DED in Spain
8.5.4.2. Gender-specific Diagnosed Prevalent Cases of DED in Spain
8.5.4.3. Age-specific Diagnosed Prevalent Cases of DED in Spain
8.5.4.4. Severity-specific Diagnosed Prevalent Cases of DED in Spain
8.5.5. The United Kingdom
8.5.5.1. Total Diagnosed Prevalent Cases of DED in the UK
8.5.5.2. Gender-specific Diagnosed Prevalent Cases of DED in the UK
8.5.5.3. Age-specific Diagnosed Prevalent Cases of DED in the UK
8.5.5.4. Severity-specific Diagnosed Prevalent Cases of DED in the UK
8.6. Japan
8.6.1. Total Diagnosed Prevalent Cases of DED
8.6.2. Gender-specific Diagnosed Prevalent Cases of DED
8.6.3. Age-specific Diagnosed Prevalent Cases of DED in the US
8.6.4. Severity-specific Diagnosed Prevalent Cases of DED
9. Patient Journey10. KOL Views
11. Appendix
11.1. Bibliography
11.2. Acronyms and Abbreviations
11.3. Report Methodology
12. Publisher Capabilities13. Disclaimer14. About the Publisher
List of Tables
Table 1: Summary of Epidemiology (2020-2034)
Table 2: Comparison of Juvenile Dry Eye Disease (DED) and Adult Dry Eye Disease (DED)
Table 3: Cutaneous Manifestations of Adult Dry Eye Disease (DED)
Table 4: Systemic Manifestations of Dry Eye Disease (DED) in Adults and Children
Table 5: Bohan and Peter Classification Criteria for Polymyositis and Dry Eye Disease (DED)
Table 6: Diagnostic Criteria for Dry Eye Disease (DED)
Table 7: The European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile IIM
Table 8: Currently Used ‘Guidance for Diagnosis in Specified Pediatric Chronic Diseases
Table 9: Recommendations Regarding Diagnosis
Table 10: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the 7MM (2020-2034)
Table 11: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 12: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 13: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 14: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 15: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 16: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Table 17: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 18: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 19: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 20: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 21: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 22: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Table 23: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 24: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 25: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 26: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 27: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 28: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Table 29: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 30: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 31: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 32: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 33: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 34: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Table 35: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 36: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 37: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 38: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 39: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 40: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Table 41: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 42: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 43: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 44: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 45: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 46: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Table 47: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 48: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 49: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 50: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 51: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 52: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Table 53: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Table 54: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Table 55: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Table 56: Severity-specific Diagnosed Prevalent cases of Dry Eye Disease (DED) in Japan (2020-2034)
Table 57: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Table 58: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
List of Figures
Figure 1: Signs and Symptoms of Dry Eye Disease (DED)
Figure 2: Contributing Factors to Dry Eye Disease (DED)
Figure 3: Causes of Dry Eye Disease (DED)
Figure 4: Complications Associated With Dry Eye Disease (DED)
Figure 5: The Vicious Pro-inflammatory Circle in Dry Eye Disease (DED)
Figure 6: Classification Tree for a Subtype of IIM
Figure 7: Patient Journey of Dry Eye Disease (DED)
Figure 8: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the 7MM (2020-2034)
Figure 9: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 10: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 11: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 12: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 13: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 14: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the US (2020-2034)
Figure 15: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 16: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 17: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 18: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 19: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 20: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in EU4 and the UK (2020-2034)
Figure 21: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 22: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 23: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 24: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 25: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 26: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Germany (2020-2034)
Figure 27: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 28: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 29: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 30: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 31: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 32: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in France (2020-2034)
Figure 33: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 34: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 35: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 36: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 37: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 38: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Italy (2020-2034)
Figure 39: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 40: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 41: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 42: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 43: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 44: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Spain (2020-2034)
Figure 45: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 46: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 47: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 48: Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 49: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 50: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the UK (2020-2034)
Figure 51: Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 52: Age-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 53: Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 54: Severity-specific Diagnosed Prevalent cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 55: Chronicity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 56: Comorbidity-specific Diagnosed Prevalent Cases of Dry Eye Disease (DED) in Japan (2020-2034)
Figure 57: Patient Journey

Related Topics

Related Reports

Dry Eye Treatment Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Dry Eye Treatment Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 101 Pages
  • Global
From
Dry Eye Syndrome Treatment Market Size, Share & Trends Analysis Report By Type, By Drug, By Product, By Dosage Form, By Sales Channel, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Dry Eye Syndrome Treatment Market Size, Share & Trends Analysis Report By Type, By Drug, By Product, By Dosage Form, By Sales Channel, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Dry Eye Syndrome Market Report by Disease Type, Drug Type, Product, Distribution Channel, and Region 2024-2032 - Product Image

Dry Eye Syndrome Market Report by Disease Type, Drug Type, Product, Distribution Channel, and Region 2024-2032

  • Report
  • 144 Pages
  • Global
From
Dry Eye Syndrome Market by Drug, Product - Global Forecast 2025-2030 - Product Image

Dry Eye Syndrome Market by Drug, Product - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Dry Eye Medication Market Report 2024 - Product Image

Dry Eye Medication Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.